WHAT IS LUMOXITI?
LUMOXITI is a prescription medicine used to treat adults with hairy cell leukemia (HCL):
- That has come back or has not responded to previous treatment, and
- Have received at least 2 other treatments, including a type of medicine called purine nucleoside analog (PNA)
It is not known if LUMOXITI is safe and effective in children.
LUMOXITI is not chemotherapy.
HOW DOES LUMOXITI WORK?
LUMOXITI attaches to CD22, a type of protein found on hairy cells.
HOW HAS LUMOXITI BEEN STUDIED?
LUMOXITI has been evaluated in the largest clinical study to date of adults with HCL whose disease had returned following at least 2 previous treatments:
- This study included a total of 80 adults with hairy cell leukemia who received treatment with LUMOXITI
- All people in this study received at least 2 other types of treatment before receiving LUMOXITI, including a type of medicine called a purine nucleoside analog
How effective was LUMOXITI in the clinical study?
Throughout the study, doctors checked to see how well each person responded to treatment with LUMOXITI:
- If by the end of treatment no evidence of hairy cell leukemia was seen in the bone marrow or blood, this was called a “complete response”
- People who had a complete response were then followed for more than 180 days to see if the response lasted
A total of 24 of the 80 people in the study, or 30%, had a complete response to treatment that lasted more than 180 days.
Other Study Results
- In all, 60 out of 80 people in the study, or 75%, responded to treatment with LUMOXITI. Of these:
- 33 people, or 41%, had a complete response during treatment
- 27 people, or 34%, had a partial response, meaning that the amount of HCL cells in their bodies decreased during treatment